Tharimmune raises $2.02M in private placement for TH104 development

Canton Strategic Holdings, Inc.

Gross proceeds of ~$2.02M from issuance of 961,446 common shares (or equivalents) and warrants for 480,723 shares at $2.10 per unit.
Warrants exercisable at $2.031/share, starting 6 months after issuance, expiring in 5.5 years.
Placement led by Gravitas Capital and SDS Capital Group; President Street Global as exclusive agent.
Net proceeds to fund clinical development of TH104 (pruritus in PBC) and working capital.
Closing expected on or about December 9, 2024, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.